ATE333288T1 - Gezielte freisetzung von arzneimitteln zur behandlung von virusinfektionen - Google Patents
Gezielte freisetzung von arzneimitteln zur behandlung von virusinfektionenInfo
- Publication number
- ATE333288T1 ATE333288T1 AT02736575T AT02736575T ATE333288T1 AT E333288 T1 ATE333288 T1 AT E333288T1 AT 02736575 T AT02736575 T AT 02736575T AT 02736575 T AT02736575 T AT 02736575T AT E333288 T1 ATE333288 T1 AT E333288T1
- Authority
- AT
- Austria
- Prior art keywords
- treatment
- virus infections
- medicinal products
- targeted release
- viral
- Prior art date
Links
- 241000700605 Viruses Species 0.000 title abstract 2
- 208000015181 infectious disease Diseases 0.000 title 1
- 229940126601 medicinal product Drugs 0.000 title 1
- 239000003443 antiviral agent Substances 0.000 abstract 3
- 102000011409 Transcobalamins Human genes 0.000 abstract 2
- 108010023603 Transcobalamins Proteins 0.000 abstract 2
- 102000004338 Transferrin Human genes 0.000 abstract 2
- 108090000901 Transferrin Proteins 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000012581 transferrin Substances 0.000 abstract 2
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 abstract 1
- 231100000742 Plant toxin Toxicity 0.000 abstract 1
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 229940100198 alkylating agent Drugs 0.000 abstract 1
- 239000002168 alkylating agent Substances 0.000 abstract 1
- 230000006907 apoptotic process Effects 0.000 abstract 1
- 230000001580 bacterial effect Effects 0.000 abstract 1
- 230000003115 biocidal effect Effects 0.000 abstract 1
- 231100000433 cytotoxic Toxicity 0.000 abstract 1
- 230000001472 cytotoxic effect Effects 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 239000003123 plant toxin Substances 0.000 abstract 1
- 230000010076 replication Effects 0.000 abstract 1
- 239000003053 toxin Substances 0.000 abstract 1
- 231100000765 toxin Toxicity 0.000 abstract 1
- 108700012359 toxins Proteins 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/644—Transferrin, e.g. a lactoferrin or ovotransferrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29066801P | 2001-05-15 | 2001-05-15 | |
| US35539402P | 2002-02-08 | 2002-02-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE333288T1 true ATE333288T1 (de) | 2006-08-15 |
Family
ID=26966345
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02736575T ATE333288T1 (de) | 2001-05-15 | 2002-05-15 | Gezielte freisetzung von arzneimitteln zur behandlung von virusinfektionen |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US8183208B2 (de) |
| EP (1) | EP1395273B1 (de) |
| JP (1) | JP2004537515A (de) |
| CN (1) | CN100372566C (de) |
| AT (1) | ATE333288T1 (de) |
| CA (1) | CA2447335C (de) |
| DE (1) | DE60213232T2 (de) |
| PL (1) | PL367244A1 (de) |
| WO (1) | WO2002092116A1 (de) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004532245A (ja) | 2001-05-15 | 2004-10-21 | ページ ダブル フォーク | 癌を治療するための生体影響性化合物の標的送達 |
| ATE333288T1 (de) | 2001-05-15 | 2006-08-15 | Faulk Pharmaceuticals Inc | Gezielte freisetzung von arzneimitteln zur behandlung von virusinfektionen |
| CA2447395A1 (en) * | 2001-05-16 | 2002-11-21 | Faulk Pharmaceuticals, Inc. | Targeted delivery of drugs for the treatment of parasitic infections |
| EP1478393A4 (de) * | 2002-02-07 | 2006-02-08 | Massachusetts Inst Technology | Gegen erreger gerichtete behandlungen |
| WO2012138911A2 (en) * | 2011-04-05 | 2012-10-11 | The Administrators Of The Tulane Educational Fund | Conjugates of anti-hiv drugs and somatostatin analogs |
| EP2841107B1 (de) * | 2012-04-26 | 2021-11-03 | Yale University | Gegen hiv gerichtete zytotoxische wirkstoffe freisetzende moleküle (cdm-hs), zytotoxische wirkung gegen das menschliche immunschwächevirus und verfahren zur verwendung |
| CN107304424B (zh) * | 2016-05-23 | 2019-05-10 | 成都福际生物技术有限公司 | 改造的转铁蛋白dna结合域、重组dna聚合酶及制备方法 |
| WO2018031967A1 (en) * | 2016-08-12 | 2018-02-15 | L.E.A.F. Holdings Group Llc | Polyglutamated antifolates and uses thereof |
| CN116194146A (zh) * | 2020-07-14 | 2023-05-30 | 詹正雄 | 用于递送生物活性剂的组合物及其制造方法和用途 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2116979B (en) | 1982-02-25 | 1985-05-15 | Ward Page Faulk | Conjugates of proteins with anti-tumour agents |
| US5108987A (en) * | 1982-02-25 | 1992-04-28 | Faulk Ward P | Conjugates of proteins with anti-tumor agents |
| GB8519457D0 (en) | 1985-08-02 | 1985-09-11 | Faulk Ward Page | Tumour imaging agents |
| IN165717B (de) | 1986-08-07 | 1989-12-23 | Battelle Memorial Institute | |
| IL89220A (en) * | 1988-02-11 | 1994-02-27 | Bristol Myers Squibb Co | Anthracycline immunoconjugates, their production and pharmaceutical compositions containing them |
| US5688488A (en) | 1989-04-03 | 1997-11-18 | Purdue Research Foundation | Composition and method for tumor imaging |
| US5208323A (en) * | 1989-08-10 | 1993-05-04 | Universite Laval | Coupling of an anti-tumor to an antibody using glutaraldehyde preactivated anti-tumor agent |
| US5238940A (en) | 1990-03-22 | 1993-08-24 | Quadra Logic Technologies Inc. | Compositions for photodynamic therapy |
| US5268165A (en) | 1990-10-16 | 1993-12-07 | Biomedical Frontiers, Inc. | Polymer-deferoxamine-ferric iron adducts for use in magnetic resonance imaging |
| US5326778A (en) | 1992-03-03 | 1994-07-05 | Research Corporation Technologies, Inc. | Conjugates of biotin and deferoxamine for radioimmunoimaging and radioimmunotherapy |
| DE4435087A1 (de) | 1994-09-30 | 1996-04-04 | Deutsches Krebsforsch | Konjugat zur Behandlung von Infektions-, Autoimmun- und Hauterkrankungen |
| US6066319A (en) * | 1996-04-30 | 2000-05-23 | President And Fellows Of Harvard College | Drug delivery using terminal complement components |
| EP0923738A1 (de) * | 1996-06-11 | 1999-06-23 | Advanced Research & Technology Institute | Verfahren und zubereitungen für die verwendung von apurinischen/apyrimidinischen endonukleasen |
| DE19636889A1 (de) | 1996-09-11 | 1998-03-12 | Felix Dr Kratz | Antineoplastisch wirkende Transferrin- und Albuminkonjugate zytostatischer Verbindungen aus der Gruppe der Anthrazykline, Alkylantien, Antimetabolite und Cisplatin-Analoga und diese enthaltende Arzneimittel |
| WO2000033884A1 (en) * | 1998-12-04 | 2000-06-15 | Oregon Health Sciences University | Conjugates of lipids and antimicrobial or antineoplastic drugs |
| GB9908195D0 (en) * | 1999-04-09 | 1999-06-02 | Microbiological Res Authority | Treatment of intracellular infection |
| AUPQ014699A0 (en) | 1999-05-04 | 1999-05-27 | Access Pharmaceuticals Australia Pty Limited | Amplification of folate-mediated targeting to tumor cells using nanoparticles |
| EP1305051A4 (de) | 2000-06-28 | 2007-01-10 | Ward Page Faulk | Gezielte verabreichung von zytotoxischen wirkstoffen a) an aktivierte lymphocyten in patienten mit transplantierten organen, b) als strahlungssensibilisatoren an krebszellen bei strahlentherapierten patienten, und c) in vitamin-bindenden proteinen als wirkstoffträger in der diagnose und behandlung von krebs |
| US20020137901A1 (en) | 2001-01-22 | 2002-09-26 | Cavanaugh Philip Gerard | Synthesis, and photodynamic therapy-mediated anti-cancer, and other uses of chlorin e6-transferrin |
| US6548531B2 (en) * | 2001-02-09 | 2003-04-15 | Hoffmann-La Roche Inc. | Method for cancer therapy |
| US6905669B2 (en) * | 2001-04-24 | 2005-06-14 | Supergen, Inc. | Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase |
| FR2824563B1 (fr) | 2001-05-10 | 2004-12-03 | Bio Merieux | Particules composites, conjugues derives, procede de preparation et applications |
| ATE333288T1 (de) | 2001-05-15 | 2006-08-15 | Faulk Pharmaceuticals Inc | Gezielte freisetzung von arzneimitteln zur behandlung von virusinfektionen |
| PL373511A1 (en) * | 2001-05-15 | 2005-09-05 | Faulk Pharmaceuticals, Inc. | Substantially homogeneous bio-affecting material having a pre-determined ratio of bioaffecting component to cell targeting component, the method for making such a material and the method of its use |
| JP2004532245A (ja) * | 2001-05-15 | 2004-10-21 | ページ ダブル フォーク | 癌を治療するための生体影響性化合物の標的送達 |
| CA2447395A1 (en) | 2001-05-16 | 2002-11-21 | Faulk Pharmaceuticals, Inc. | Targeted delivery of drugs for the treatment of parasitic infections |
| WO2003032899A2 (en) | 2001-10-17 | 2003-04-24 | Faulk Pharmaceuticals, Inc | Methods and materials for targeting and affecting selected cells |
-
2002
- 2002-05-15 AT AT02736575T patent/ATE333288T1/de not_active IP Right Cessation
- 2002-05-15 WO PCT/US2002/011892 patent/WO2002092116A1/en not_active Ceased
- 2002-05-15 PL PL02367244A patent/PL367244A1/xx not_active Application Discontinuation
- 2002-05-15 DE DE60213232T patent/DE60213232T2/de not_active Expired - Lifetime
- 2002-05-15 CN CNB028142411A patent/CN100372566C/zh not_active Expired - Fee Related
- 2002-05-15 EP EP02736575A patent/EP1395273B1/de not_active Expired - Lifetime
- 2002-05-15 CA CA2447335A patent/CA2447335C/en not_active Expired - Fee Related
- 2002-05-15 JP JP2002589033A patent/JP2004537515A/ja active Pending
-
2008
- 2008-01-03 US US11/968,904 patent/US8183208B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN1529612A (zh) | 2004-09-15 |
| CN100372566C (zh) | 2008-03-05 |
| DE60213232D1 (de) | 2006-08-31 |
| CA2447335A1 (en) | 2002-11-21 |
| PL367244A1 (en) | 2005-02-21 |
| JP2004537515A (ja) | 2004-12-16 |
| WO2002092116A1 (en) | 2002-11-21 |
| US20080103094A1 (en) | 2008-05-01 |
| US8183208B2 (en) | 2012-05-22 |
| EP1395273B1 (de) | 2006-07-19 |
| DE60213232T2 (de) | 2007-07-26 |
| EP1395273A1 (de) | 2004-03-10 |
| EP1395273A4 (de) | 2004-08-18 |
| CA2447335C (en) | 2011-01-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GEP20084545B (en) | Introducing tlr7 ligands and prodrugs thereof for the treatment of hepatitis c viral infection | |
| DK0746327T3 (da) | Forsuret nitrit som antimikrobielt middel | |
| NZ515392A (en) | Respiratory syncytial virus replication inhibitors | |
| CO5280056A1 (es) | Alimento para mascotas destinado al tratamiento de la especie helicobacter en las mascotas | |
| NO20061736L (no) | Krystallform av epotilon B | |
| TNSN96099A1 (fr) | Inhiber la croissance des bacteries dans les articles absorbants en ajoutant d'autres bacteries | |
| PT1326635E (pt) | Composicao farmaceutica para imunizacao contra a sida | |
| NO20064547L (no) | Fremgangsmater for behandling av HIV infeksjon | |
| BRPI0507628A (pt) | composto ou sal farmaceuticamente aceitável do mesmo, método de tratamento de uma infecção viral em um ser humano, uso de um composto composição farmacêutica, e, processo para a preparação de um composto | |
| NO951198L (no) | Lipopeptidderivater, fremgangsmåte for fremstilling derav og anvendelse av derivatene | |
| ATE333288T1 (de) | Gezielte freisetzung von arzneimitteln zur behandlung von virusinfektionen | |
| DE69835536D1 (de) | Zusammensetzungen zur behandlung von staphylococcus aureus infektionen | |
| PT1057828E (pt) | Suspensoes de trovafloxacina para administracao oral | |
| EA200400197A1 (ru) | Способы получения поливалентных бактериофагов для лечения бактериальных инфекций | |
| NZ505894A (en) | Methylenebisbenzaldehyde derivatives, methylidynetrisphenol derivative and pharmaceuticals thereof; useful for treating or preventing pneumovirus infection and associated diseases | |
| NZ510153A (en) | Tan-1057 derivatives with reduced toxicity and their use in medicaments for treating bacterial infections in humans and mammals | |
| YU68602A (sh) | Monoklonska antitela na humani ldl receptor, njihova produkcija i korišćenje | |
| PT1140113E (pt) | Utilizacao de bisfosfonatos para profilaxia e tratamento de processos infecciosos | |
| EP1395264A4 (de) | Gezielte freisetzung von arzneimitteln zur behandlung von parasitischen infektionen | |
| WO2009008924A3 (en) | Methods of preventing and treating viral infections by inhibiting the deisgylation activity of otu domain-containing viral proteins | |
| ATE433459T1 (de) | Desoxo-nonadepsipeptide | |
| AU2002327970A1 (en) | Inhibitors of costimulation by 0x40 and their use against infectious diseases | |
| ATE261732T1 (de) | Pharmazeutische zusammensetzung, umfassend eukalyptus- und orangenöl | |
| ATE410154T1 (de) | Pharmazeutische zusammensetzung enthaltend 2,4- dichlorbenzylalkohol und amylmetakresol | |
| AU2396900A (en) | Treatment and prevention of hiv and other viral infections |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |